-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Inclusion Body Myositis (IBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Inclusion Body Myositis (IBM) Drug Details: Froniglutide (formerly PB-1023) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide [Inn] in Becker Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Froniglutide [Inn] in Becker Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Froniglutide [Inn] in Becker Muscular DystrophyDrug Details:Froniglutide (formerly PB-1023) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-1804 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-1804 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PF-1804 in Duchenne Muscular DystrophyDrug Details:PF-1804 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-1804 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-1804 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PF-1804 in Congestive Heart Failure (Heart Failure)Drug Details:PF-1804 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-1804 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-1804 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PF-1804 in Cystic FibrosisDrug Details:PF-1804 is under development for the treatment of cystic...
-
Product Insights
Hydrogels Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hydrogels Pipeline Market Report Overview Hydrogels include dressings that consist of 96% water with a matrix of insoluble polymers embedded in it. The former helps to maintain a moist wound environment while the latter facilitates absorption of wound exudates. These dressings are available in the form of tubes and sheets and both of them are tracked under this segment. Hydrogels are segmented into antimicrobial and non-antimicrobial hydrogel dressings. The Hydrogels pipeline market research report provides comprehensive information about the Hydrogels...
-
Product Insights
Flughafen Zurich – Expansion of the Land-Based Passenger Area (ELP) – Zurich
Equip yourself with the essential tools needed to make informed and profitable decisions with our Flughafen Zurich - Expansion of the Land-Based Passenger Area (ELP) - Zurich report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Company Profile
PhaseBio Pharmaceuticals Inc – Company Profile
PhaseBio Pharmaceuticals Inc (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company's pipeline products comprise of PB2452, a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor; PB1046 is a subcutaneously-injected, sustained release analogue of the native human peptide vasoactive intestinal peptide (VIP) used for the treatment of pulmonary arterial hypertension. PhaseBio proprietary ELP Biopolymer technology platform extends the circulating half-life of proteins...
Add to Basket -
Company Profile
Equity Lifestyle Properties Inc – Company Profile
Equity Lifestyle Properties Inc (ELP) is a provider of real estate investment services. The company owns and manages lifestyle-oriented properties. Its portfolio comprises manufactured home communities, campgrounds, and recreational vehicle resorts. The company’s properties are featured with various amenities and common facilities including clubhouses, cable television service, laundry facilities, internet services and swimming pools. It also provides homes for vacationing families, second homeowners and retirees at a lower cost. As of December 31, 2022, the company owned and operated 449...
Add to Basket -
Product Insights
Short Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness, and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones, and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors, and bile-salt binders The Short Bowel Syndrome pipeline drugs market research report provides comprehensive information on...